Abiopharma

Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

New Form SCHEDULE 13G/A - Viatris Inc <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 0001036325-26-000013 <b>Size:</b> 6 KB

(30% Negative) USA COMPRESSION PARTNERS, LP (USAC) Reports Q2 2026 Financial Results

(99% Neutral) OIL STATES INTERNATIONAL, INC (OIS) Reports Q2 2026 Financial Results

Mandatory Cash Dividend/ Distribution:

(30% Negative) FIRST WATCH RESTAURANT GROUP, INC. (FWRG) Reports Q2 2026 Financial Results

Avanos Medical, Inc. Announces First Quarter 2026 Results

(75% Negative) MARRIOTT VACATIONS WORLDWIDE CORP (VAC) Reports Q2 2026 Financial Results

(10% Negative) AIFUL CORP. (ULS) Reports Q2 2026 Financial Results

(99% Neutral) TRANSOCEAN LTD. (RIG) Announces Business Combination

Castle Biosciences - Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

(99% Neutral) PFIZER INC (PFE) Reports Q2 2026 Financial Results

New Form S-8 POS - Terns Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 0001193125-26-205373 <b>Size:</b> 31 KB

Johnson & Johnson - Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

FELTHEIMER JON 🟡 adjusted position in 8.9K shares (3 derivative) of GRUPO TELEVISA, S.A.B. (TV) at $0.46 Transaction Date: Apr 30, 2026 | Filing ID: 000178